Terms: = Cervical cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
64 results:
1. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract] [Full Text] [Related]
2. Clinical significance of integrin αV and β superfamily members and focal adhesion kinase activity in oral squamous cell carcinoma: a retrospective observational study.
Sakurai S; Ishida Y; Shintani T; Yamasaki S; Matsui K; Hamana T; Nobumoto T; Yanamoto S; Hayashido Y
Pathol Oncol Res; 2024; 30():1611571. PubMed ID: 38312516
[No Abstract] [Full Text] [Related]
3. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract] [Full Text] [Related]
4. cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
Miyama Y; Kato T; Sato M; Yabuno A; Hasegawa K; Yasuda M
Diagn Pathol; 2024 Jan; 19(1):6. PubMed ID: 38178127
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract] [Full Text] [Related]
6. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a prognostic model based on immune and hypoxia-related gene expressions in cervical cancer.
Wang L; Wang C; He Y; Jin M; Lin L; Jiao X; Hu X; Wang Y
J Obstet Gynaecol; 2023 Dec; 43(2):2277242. PubMed ID: 37938121
[TBL] [Abstract] [Full Text] [Related]
8. NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in cervical cancer.
Chen X; Hao Y; Liu Y; Zhong S; You Y; Ao K; Chong T; Luo X; Yin M; Ye M; He H; Lu A; Chen J; Li X; Zhang J; Guo X
Adv Sci (Weinh); 2023 Nov; 10(32):e2302705. PubMed ID: 37818745
[TBL] [Abstract] [Full Text] [Related]
9. Expression of b7-h3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with pd-l1 expression, and prognostic significance.
Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
[TBL] [Abstract] [Full Text] [Related]
10. Invasive stratified mucin-producing carcinoma (ISMC) of the cervix: a clinicopathological and molecular analysis of 59 cases with special emphasis on histogenesis and potential therapeutic targets.
Yao Y; Wang Y; Ye L; Lu B; Lu W
Histopathology; 2024 Jan; 84(2):315-324. PubMed ID: 37735961
[TBL] [Abstract] [Full Text] [Related]
11. Prevalence and prognostic role of pd-l1 in patients with gynecological cancers: A systematic review and meta-analysis.
Fu H; Fu Z; Mao M; Si L; Bai J; Wang Q; Guo R
Crit Rev Oncol Hematol; 2023 Sep; 189():104084. PubMed ID: 37536446
[TBL] [Abstract] [Full Text] [Related]
12. Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances.
Chao A; Wu RC; Lin CY; Chang TC; Lai CH
Biomed J; 2023 Oct; 46(5):100633. PubMed ID: 37467967
[TBL] [Abstract] [Full Text] [Related]
13. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract] [Full Text] [Related]
14. An integrated model for prognosis in vulvar squamous cell carcinoma.
Zhang T; Zhu Y; Luo J; Li J; Niu S; Chen H; Zhou F
BMC Cancer; 2023 Jun; 23(1):534. PubMed ID: 37308869
[TBL] [Abstract] [Full Text] [Related]
15. Infection pattern and immunological characteristics of Epstein-Barr virus latent infection in cervical squamous cell carcinoma.
Zuo Y; Xiao H; Lv D; Huang M; Wang L; Liu J; Zhang K; Shen J; Wang Z; Wu Q; Xu Y
J Med Virol; 2023 Apr; 95(4):e28717. PubMed ID: 37184049
[TBL] [Abstract] [Full Text] [Related]
16. Assessment of HER2 in Gastric-Type Endocervical Adenocarcinoma and its Prognostic Significance.
Wang S; Zhou X; Niu S; Chen L; Zhang H; Chen H; Zhou F
Mod Pathol; 2023 Jun; 36(6):100148. PubMed ID: 36841435
[TBL] [Abstract] [Full Text] [Related]
17. Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study.
Miyata Y; Ogo E; Abe T; Hirata H; Tsuda N; Ushijima K; Kawahara A; Akiba J; Obara H; Kakuma T
Radiat Oncol; 2023 Feb; 18(1):40. PubMed ID: 36823665
[TBL] [Abstract] [Full Text] [Related]
18. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
[TBL] [Abstract] [Full Text] [Related]
19. Tumor associated macrophage in HPV
Gorvel L; Olive D
Semin Immunol; 2023 Jan; 65():101671. PubMed ID: 36459926
[TBL] [Abstract] [Full Text] [Related]
20. Adenoid Basal Carcinoma with Adenoid Cystic Carcinoma Component of the Uterine Cervix: A Case Report and Literature Review.
Kitamura SI; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2023 Aug; 31(5):819-824. PubMed ID: 36452999
[TBL] [Abstract] [Full Text] [Related]
[Next]
